Myriad, SimonMed Join in Genetic Risk Assessment Program

  Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, and SimonMed® Imaging, one of the largest independent outpatient medical imaging providers and physician radiology practices in the United States, today announced the planned launch of a new hereditary cancer assessment program that combines diagnostic imaging, genetic risk assessment utilizing MyRisk® with RiskScore® and patient education. Leveraging a custom-built Myriad tool developed in collaboration with SimonMed, the program is expected to enable affordable access to genetic testing and deliver personalized insights to better inform clinical decisions for the millions of patients and families served at SimonMed.

For more than 30 years, Myriad and SimonMed have worked independently to help millions of patients understand their health and well-being through genetic testing and diagnostic imaging. The collaboration will bring together the strengths of Myriad’s risk assessment resources and hereditary cancer test, MyRisk with RiskScore, and SimonMed’s deep expertise in the medical imaging space.

https://finance.yahoo.com/news/myriad-genetics-simonmed-imaging-collaborate-120000636.html

Arrowhead to Host R&D Day on Pipeline of RNAi Therapeutics

 Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a Research & Development (R&D) Day on June 1, 2023, beginning at 9 a.m. ET in New York City to discuss progress towards the company’s "20 in 25" goal to grow its pipeline of RNAi therapeutics that leverage the proprietary Targeted RNAi Molecule (TRiMTM) platform to a total of 20 clinical stage or marketed products in the year 2025.

Arrowhead also announced that company has expanded its TRiMTM platform to include an optimized intrathecal administration for central nervous system (CNS) delivery with good distribution throughout the brain and in all relevant brain cell types. The first development candidate to utilize this new delivery platform, ARO-SOD1, is on track for a clinical trial application (CTA) filing in the third quarter of 2023 to begin clinical studies.

ARO-SOD1 is designed to reduce expression of superoxide dismutase 1 (SOD1) in the CNS as a potential treatment for patients with amyotrophic lateral sclerosis (ALS) caused by SOD1 mutations. ARO-SOD1 was highly active against its target with a long duration of effect in multiple preclinical models suggesting that it may be administered quarterly or less frequently. In preclinical studies, ARO-SOD1 achieved 95% spinal cord tissue mRNA knockdown after a single intrathecal dose in human SOD1 transgenic rats and maintained greater than 80% spinal cord tissue mRNA knockdown three months after a single intrathecal dose in non-human primates.

The R&D Day will feature presentations by three key opinion leaders: Ira Goldberg, M.D. (NYU Langone Medical Center), who will discuss the unmet medical need in treating patients with hypertriglyceridemia and mixed dyslipidemia in atherosclerotic cardiovascular disease (ASCVD); Matthias Salathe, M.D. (University of Kansas Medical Center), who will discuss the muco-obstructive and inflammatory pulmonary disease landscape; and Michael Benatar, M.D., Ph.D. (University of Miami Miller School of Medicine), who will discuss ALS caused by SOD1 mutations. Drs. Goldberg, Salathe, and Benatar will be available to answer questions following their presentations.

https://finance.yahoo.com/news/arrowhead-pharmaceuticals-host-r-d-113000736.html

Majority Of New Yorkers Feel Subway Unsafe At Night, Quarter Worry About Safety During The Day

 by Petr Svab via The Epoch Times (emphasis ours),

More than half of residents feel unsafe riding the New York City subway alone at night and one in four feels that way even in the daytime, according to a survey conducted earlier this year.

The numbers are even higher for women and Asian Americans, two-thirds of whom feel unsafe at night and about a third of whom feel unsafe during the day.

Residents felt more worried about waiting for a train on the platform than riding the train itself.

The survey follows a series of high-profile crimes on the subway in recent years where people have been assaulted or even pushed onto the tracks. Victims have disproportionately been women and Asian Americans. Perpetrators have disproportionately been black men.

Yet the level of crime in the subway system, in general, hasn’t changed much over the past decade and is even slightly down so far this year compared to last year, according to New York City Police Department data.

What has increased dramatically, however, is crime in the city more broadly. Felony assaults, in particular, have been on the rise for years and so far this year have been at their highest since 1998. Also up are petty theft such as shoplifting, misdemeanor assaults, and car theft. Murder has somewhat declined this and last year, but is still up from 2019 after a dramatic rise in 2020 and 2021.

But New Yorkers still feel the city streets are safer than the subway, according to the survey. Sixty-eight percent said they felt safe walking down the street alone during the day compared to 58 percent feeling safe riding the subway alone. At night, 59 percent felt unsafe riding the subway alone, but only 50 percent felt unsafe walking alone.

https://www.zerohedge.com/political/majority-new-yorkers-feel-subway-unsafe-night-quarter-worry-about-safety-during-day-poll

NeuroOne Successful Trial Could Help Eliminate Need For Incision with Back Pain

 From reduced healthcare costs to smaller incisions, less scarring, increased accuracy, decreased risk of complications, less pain and shorter recovery, MIS presents a lot of benefits to patients compared to an open technique.

The industry started its rapid growth in the 1980s with the advent of laparoscopic surgery, and since then, it has only continued to expand. Today, MIS technology - like that of NeuroOne Medical Technologies Corp. (NASDAQ:NMTC) - is used in a wide range of procedures, including neurosurgery, gynecological, urological, and cardiovascular surgeries. With chronic disease prevalence on the rise, the market continues to grow - it is projected to grow at a compound annual growth rate (CAGR) of 10.4% over 2022-2030 to reach a total value of $70 billion by 2030.

Advancements in medical imaging of the human body have helped minimally invasive procedures grow. By being able to get a better view of the surgical area, surgeons can perform even more delicate procedures with greater accuracy. It is believed that as new technologies continue to evolve, it's only a matter of time before even more extensive surgical operations will be conducted in a minimally invasive way.

One significant factor that has also contributed to the growth of MIS is the technological advances in instrument development and robotic surgery, which allows surgeons to perform complex procedures with greater precision and control. Robotic or instrument surgery also eliminates hand tremors and ensures a steadier hand while operating, lowering the risk of complications.

The talk of technological advances in instrument development playing a pivotal role in the upward trend of MIS brings to the fore the work of NeuroOne, one of the companies committed to providing such surgical solutions.

https://finance.yahoo.com/news/minimally-invasive-surgery-companys-successful-131500872.html

FSD Pharma Announces Plan to Spin-Out Subsidiary

 FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, is pleased to announce it intends to complete a spin-out transaction via a plan of arrangement (the "Plan of Arrangement") under the Business Corporations Act (Ontario) (the "Spin-out Transaction") whereby the shares of its yet-to-be-formed wholly owned subsidiary ("Pubco") will be separated into an independent public company. The Spin-out Transaction, which is expected to be completed in July 2023, is intended to enable the Company to focus on development of its core assets and maximize shareholder value.

All shareholders of the Company (the "Shareholders") as of the distribution date (the "Distribution Date") will exchange their shares in the capital of the Company (each, inclusive of both Class A multiple voting shares and Class B subordinate voting shares, an "FSD Share") for the same number of existing shares of the Company (having identical terms, both for the Class A multiple voting shares and Class B subordinate voting shares) plus common shares in the capital of the Pubco (each, a "Pubco Share"), on a pro rata basis. Pubco will only have one class of shares.

Shareholders must hold FSD Share as of the Distribution Date to qualify to receive shares of Pubco in the distribution. FSD Pharma will provide further updates on the Distribution Date in due course.

Following the Spin-out Transaction, FSD Pharma will remain listed on the NASDAQ Stock Market and Canadian Securities Exchange (the "CSE"). Following the Spin-out Transaction, Pubco will become a "reporting issuer" in the same jurisdictions in Canada that FSD Pharma is a reporting issuer, with a view to completing a reverse take-over transaction with a business that has yet to be identified.

https://finance.yahoo.com/news/fsd-pharma-announces-plan-spin-123000594.html

Vuzix: Volume Follow-on Smart Glasses Order from Acuraflow to Supply Pharma Customer

  Vuzix® Corporation (NASDAQ: VUZI), ("Vuzix" or, the "Company"), a leading supplier of Smart Glasses and Augmented Reality (AR) technology and products, today announced that it has received and shipped against a volume follow-on order for Vuzix smart glasses from Acuraflow, a developer and deployer of sustainable management solutions. The follow-on order was placed to primarily supply a customer in the pharmaceutical industry.

Acuraflow, established 67 years ago under the name of and doing business as Bruno Schillig, primarily serves the oil and gas, chemical, mining, utilities, automotive, pharmaceutical, and food and beverage industries. Originally focused on Argentina, the company has since expanded to the United States and Latin America.

https://finance.yahoo.com/news/vuzix-receives-volume-smart-glasses-130100232.html

Creative Medical Technology: Positive Top-Line Results for Type 2 Diabetes Study

 One-Year Follow-Up Results Confirm Significant Efficacy and No Serious Adverse Effects in Patients Using CELZ-001 for Treating Type 2 Diabetes --

Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a leading biotechnology company focused on a regenerative approach to immunotherapy, urology, gynecology, and orthopedics, today announced positive one-year follow-up data and significant efficacy using CELZ-001 to treat patients with Type 2 Diabetes without any serious adverse effects reported.

There were no safety concerns related to CELZ-001 at one year follow-up utilizing the same infusion procedure as in the currently U.S. FDA cleared CELZ-201 clinical trial. There were 30 patients in the study, 15 who received CELZ-001 and the rest received optimized medical therapy. At one year, there was an overall efficacy of 93% in the treated patients demonstrating at least a 50% reduction in insulin requirement. The Company plans to further develop this program and present the findings at an upcoming endocrinology conference.

https://finance.yahoo.com/news/creative-medical-technology-announces-positive-120000019.html